CERO THERAPEUTICS HOLDINGS INC. - COMMON STOCK

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

15 Nov 2024 08:45:00 By Nasdaq GlobeNewswire

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

11 Nov 2024 08:15:00 By Nasdaq GlobeNewswire

CERo Therapeutics, Inc. Provides Corporate Update

21 Oct 2024 09:00:00 By Nasdaq GlobeNewswire

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer

02 Oct 2024 09:15:00 By Nasdaq GlobeNewswire

CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236

25 Sep 2024 09:17:00 By Nasdaq GlobeNewswire

CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024

08 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

13 Jun 2024 08:15:00 By Nasdaq GlobeNewswire

CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236

06 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

CERo Therapeutics, Inc. Provides Corporate Update for Shareholders

15 May 2024 08:00:00 By Nasdaq GlobeNewswire

CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes

30 Apr 2024 09:00:00 By Nasdaq GlobeNewswire

Phoenix Biotech Acquisition Corp. Class A Common Shares and Warrants to Commence Trading Separately on November 26, 2021

22 Nov 2021 16:15:00 By Nasdaq GlobeNewswire

Phoenix Biotech Acquisition Corp. Announces Completion of $175,000,000 Initial Public Offering, Including Exercise of Over-Allotment Option

08 Oct 2021 16:00:00 By Nasdaq GlobeNewswire

Phoenix Biotech Acquisition Corp. Announces Pricing of $155,000,000 Initial Public Offering

05 Oct 2021 17:19:20 By Nasdaq GlobeNewswire